v3.25.2
Other Significant Agreements - Paragon Agreement (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Aug. 12, 2024
USD ($)
Nov. 30, 2023
USD ($)
Nov. 30, 2022
USD ($)
Item
shares
Jun. 30, 2025
USD ($)
shares
Dec. 31, 2024
USD ($)
shares
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2024
USD ($)
Other Significant Agreements Paragon Option Agreement                      
Research and development [1]       $ 55,703,000     $ 33,206,000     $ 102,090,000 $ 61,922,000
Issued total common units (in shares) | shares       59,587,430 59,478,725         59,587,430  
Option Agreement                      
Other Significant Agreements Paragon Option Agreement                      
Payments due upon exercise of option   $ 0                  
Paragon IL13 License Agreement | Related party                      
Other Significant Agreements Paragon Option Agreement                      
Nomination fee paid                 $ 2,000,000    
Paragon Therapeutics, Inc | Related party                      
Other Significant Agreements Paragon Option Agreement                      
Research and development       $ 100,000     2,200,000     $ 100,000 $ 8,700,000
Paragon Therapeutics, Inc | Option Agreement                      
Other Significant Agreements Paragon Option Agreement                      
Payments due upon exercise of option     $ 0                
Termination period of agreement   30 days 30 days                
Period of material breach   30 days 30 days                
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice   30 days 30 days                
Payment of non-refundable fees               $ 2,000,000      
Paragon Therapeutics, Inc | Option Agreement | Related party                      
Other Significant Agreements Paragon Option Agreement                      
Number of selected targets initially included under the agreement | Item     2                
Upfront cash amount paid     $ 1,300,000                
Issued common units (in shares) | shares     1,250,000                
Non-refundable fee   $ 2,000,000 $ 500,000                
Paragon Therapeutics, Inc | Option Agreement | Maximum | Related party                      
Other Significant Agreements Paragon Option Agreement                      
Issued total common units (in shares) | shares     3,750,000                
Paragon Therapeutics, Inc | Paragon IL13 License Agreement                      
Other Significant Agreements Paragon Option Agreement                      
Expiration period of commercial sale     12 years                
Termination period of agreement     60 days                
Period of material breach     90 days                
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice     30 days                
Paragon Therapeutics, Inc | Paragon IL13 License Agreement | Related party                      
Other Significant Agreements Paragon Option Agreement                      
Maximum amount of achievement of development and clinical mile stones     $ 3,000,000                
Nomination fee paid     1,000,000   $ 5,000,000 $ 2,000,000 $ 1,000,000 $ 2,000,000 $ 1,000,000    
Milestone payment of trial payable     $ 2,000,000                
Paragon Therapeutics, Inc | TSLP License Agreement | Related party                      
Other Significant Agreements Paragon Option Agreement                      
Maximum amount of achievement of development and clinical mile stones $ 28,000,000                    
Nomination fee paid 3,000,000       $ 3,000,000            
Milestone payment of trial payable $ 5,000,000                    
[1] Includes related-party amounts of $98 and $130 for the three and six months ended June 30, 2025, respectively, and $2,221 and $8,678 for the three and six months ended June 30, 2024, respectively.